510(k) Report

510(k) · Cleared

Recalled · Class II · 2022

Vidas B.R.a.H.M.S. PCT Assay

K071146510(k) TraditionalCleared Oct 11, 2007170-day reviewClass II21 CFR 866.3210Recalls 1

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

bioMerieux, Inc. · NTM Antigen, Inflammatory Response Marker, Sepsis

Cleared on Oct 11, 2007 after a 170-day review. The FDA summary names its predicate without a number. 24 later devices descend from it. It has been recalled once.

Decided
Oct 11, 2007
Review
170 days
Class
Class II
Product code
NTM
Recalls
1
Predicates
0

24 later devices descend from it, 2 citing it directly.

Descendants, by year cleared 2016: 1 descendant cleared2025: 3 descendants cleared2017: 4 descendants cleared2022: 3 descendants cleared2018: 3 descendants cleared2019: 2 descendants cleared2021: 1 descendant cleared2020: 3 descendants cleared2023: 3 descendants cleared2024: 1 descendant cleared20052010201520202025
  1. This deviceK071146 Vidas B.R.a.H.M.S. PCT AssaybioMerieux, Inc. · 2007
  2. Descendant · cites it directly · 22 of its ownK160911 Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc. · 2016
  3. Descendant · 2 generations on · 21 of its ownK162827 Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc. · 2017
  4. Descendant · 3 generations on · 7 of its ownK171338 B R A H M S PCT sensitive KRYPTORBrahms GmbH · 2017
  5. Descendant · 3 generations on · 3 of its ownK210254 MeMed BVMeMed Diagnostics, Ltd. · 2021
  6. Descendant · 3 generations on · 2 of its ownK220991 IntelliSep testCytovale, Inc. · 2022

Showing 5 of 24 descendants. See all descendants

Descendants cleared per year

2016: 12017: 42018: 32019: 22020: 32021: 12022: 32023: 32024: 12025: 3
2016high 4 (2017) · low 0 (2026)2026

Most influential descendants

Showing 5 of 24 · See all
  • K160911Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc. · 2016 · cites it directly22descendants
  • K162827Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc. · 2017 · 2 generations on21descendants
  • K171338B R A H M S PCT sensitive KRYPTORBrahms GmbH · 2017 · 3 generations on7descendants
  • K210254MeMed BVMeMed Diagnostics, Ltd. · 2021 · 3 generations on3descendants
  • K220991IntelliSep testCytovale, Inc. · 2022 · 3 generations on2descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)K071146Vidas B.R.a.H.M.S. PCT AssaybioMerieux, Inc.2007—
+1K160911Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc.2016—
+2K162827Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc.2017—
+3K171338B R A H M S PCT sensitive KRYPTORBrahms GmbH2017—
+3K210254MeMed BVMeMed Diagnostics, Ltd.2021—
+3K220991IntelliSep testCytovale, Inc.2022—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201610
201740
201830
201920
202030
202110
202230
202330
202410
202530
FIG. 1 — Lineage of K071146, 2007–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in NTM? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*—BRAHMS PCT LIA Assay
Named without a submission number
—

What descends from it? (24)

See all 24

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K160911Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc.201622
K242294DiaSys Procalcitonin FS; DiaSys TruCal Procalcitonin Calibrator Set; DiaSys TruLab…Diasys Diagnostic Systems GmbH20250

Has anything in its family been recalled? (0 Class I)

Recalls of this device

DateClassRecallRoot causeReason
Nov 9, 2022Class IIZ-0868-2023StorageAs the temperature and time out of range was exceeded, product performances cannot be guaranteed

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K160911 (bioMerieux, Inc., 2016) has gone furthest, with 22 descendants of its own.

How does its category compare?

All NTM devices

NTM Antigen, Inflammatory Response Marker, Sepsis: FDA decisions, review times, recalls and adverse event reports over 20 years. 2007, this device’s year, is highlighted.

FDA decisions per year · NTM

1in 2008

2007: 12008: 1
2007high 1 (2007) · low 0 (2009)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · NTM

Too few NTM 510(k)s in any year since 2007 to give a median.

Recalls per year · NTM

1in 2022

2022: 1
2007high 1 (2022) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · NTM

2in 2024

2015: 22019: 12023: 22024: 2
2007high 2 (2015) · low 0 (2007)2025

MAUDE reports naming product code NTM, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—00
20081—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—02
20160—00
20170—00
20180—00
20190—01
20200—00
20210—00
20220—10
20230—02
20240—02
20250—00
20260—0—

What is it indicated for?

VIDASC BRAHMS PCT is an automated test for use on the VIDAS instruments for the determination of human procalcitonin in human serum or plasma (lithium heparin) using the ELFA (Enzyme-Linked Fluorescent Assay) technique. The VIDAS BRAHMS PCT assay is intended for use in conjunction with other laboratory findings and clinical assessments to aid in the risk assessment of critically ill patients on their first day of ICU admission, for progression to severe sepsis and septic shock.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K071146: Vidas B.R.a.H.M.S. PCT Assay.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K071146

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026